Science Blog -- New Alzheimer's treatment Reminyl™(galantamine) completes EU mutual recognition procedureBeerse, Belgium, 12 July 2000 -- Reminyl™ (galantamine), a new treatment for Alzheimer's disease, was granted marketing approval under the Mutual Recognition Procedure by thirteen European Union member states as well as Norway and Iceland.Research indicates that Reminyl™ (galantamine), unlike other Alzheimer's treatments currently available, has a dual mechanism of action. Decreased levels of acetylcholine, caused by the death of acetylcholine neurones are known to be related to the symptoms of Alzheimer's disease. In addition to preserving levels of acetylcholine in the brain by blocking the action of the enzyme acetylcholinesterase (which inactivates acetylcholine), laboratory research has shown that Reminyl™ (galantamine) also appears to act on the brain's nicotinic receptors. The "modulation" of these receptors could lead to release of more acetylcholine.
